This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) and raised its price target to $17 from $14. The price target hike comes on the heels of the stock’s impressive 258% return over the past year.

M. A. Arkhipov/Shutterstock.com

Canaccord remains confident about the company’s long-term prospects in the aftermath of the company confirming dosing completion in both the REVEAL and ASPIRE trials in the second quarter. The company is currently advancing TSHA-102, an AAV9-based gene therapy for Rett syndrome. The FDA has already cleared initiation of the ASPIRE trial, in which three patients between 2 and 4 years old are to receive a scaled-down 1E15 dose.

Taysha Gene Therapies plans to provide updated Part A data for the trials in the second quarter, once all 12 patients have received at least 12 months of follow-up. On the other hand, interim six-month pivotal data should be available before year-end.

According to Canaccord, the significant milestone gains and clean safety profile in the pivotal trials underscore why Taysha Gene Therapies is a buy.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe, rare genetic disorders of the central nervous system. Their primary focus is TSHA-102, a promising one-time gene therapy for Rett syndrome.

READ NEXT: 7 Penny Stocks That Aren’t Scams: Best Cheap Stocks to Buy and 8 Best Small-Cap Value Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.